Results 41 to 50 of about 82,921 (179)

HEPATOTOXICIDADE SECUNDÁRIA A PEG-ASPARAGINASE EM PEDIATRIA: RELATO DE CASO

Hematology, Transfusion and Cell Therapy, 2020
J.A.S. Feitosa, A.C.R. Corrêa, J.S. Barreto, G.A.C. Ramos, A.P. Dutra, D.A.N. Krohling, L.M. Cristofani, V.O. Filho, M.T.A. Almeida, R.A.P. Teixeira   +9 more
doaj   +2 more sources

Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma

Frontiers in Pediatrics, 2022
Pediatric Acute Lymphoblastic Leukemia (ALL) cure rates have improved exponentially over the past five decades with now over 90% of children achieving long-term survival.
Luke Maese, Rachel E. Rau
doaj   +1 more source

Clinical summary of pediatric acute lymphoblastic leukemia patients complicated with asparaginase-associated pancreatitis in SCCLG-ALL-2016 protocol

Hematology, 2023
Asparaginase-associated pancreatitis (AAP) is a common and fatal complication after ASNase treatment in acute lymphoblastic leukemia(ALL). Here, a total of 1063 pediatric ALL patients treated with SCCLG-ALL-2016 regimen were collected since October 2016 ...
Jian Wang, Wen-Guang Jia, Li-Hua Yang, Wen-Yong Kuang, Li-Bin Huang, Hui-Qin Chen, Li-Na Wang, Dun-Hua Zhou, Ning Liao   +8 more
doaj   +1 more source

Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation [PDF]

, 2017
BACKGROUND: As pegylated asparaginase is becoming the preferred first-line asparaginase preparation in the chemotherapy regimens of childhood acute lymphoblastic leukemia (ALL), there is a need to evaluate this treatment.METHODS: The aim of this study ...
Skov Wehner, Peder, Gottschalk Højfeldt, Sofie, Kjeld Schmiegelow, Klug Albertsen, Birgitte, Frandsen, Thomas Leth, Louise Tram Henriksen, Peder Skov Wehner, Birgitte Klug Albertsen, Tram Henriksen, Louise, null null, Henrik Schrøder, Sofie Gottschalk Højfeldt, Schmiegelow, Kjeld, Schrøder, Henrik, Thomas Leth Frandsen   +14 more
core   +1 more source

Laporan kasus berbasis bukti: Reaksi hipersensitivitas terhadap pegylated asparaginase dibandingkan L-asparaginase pada anak dengan leukemia limfoblastik akut

Sari Pediatri, 2022
Latar belakang. L-asparaginase (L-asp) adalah regimen kemoterapi utama dalam terapi LLA pada anak. Kejadian reaksi hipersensitivitas akibat L-asp sangat tinggi, menyebabkan terapi tidak dapat dilanjutkan dan memengaruhi angka kesintasan.
Miranti Fristy Medyatama, Murti Andriastuti   +1 more
doaj   +1 more source

Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866). [PDF]

, 2022
BackgroundAdministration of L-asparaginase is limited by hypersensitivity reactions mediated by anti-asparaginase antibodies. To overcome this problem, native Escherichia coli L-asparaginase was conjugated to polyethylene glycol (PEG) to formulate PEG-L ...
Bernstein, Mark, Camitta, Bruce M, Asselin, Barbara, Pollock, Brad H, Kurtzberg, Joanne, Buchanan, George R   +5 more
core   +1 more source

Cetoacidose diabética e pancreatite secundárias à peg-asparaginase.

Medicina, 2022
Objetivos: Apresentar um caso raro de cetoacidose diabética (CAD) e pancreatite secundários ao uso de PEG-asparaginase em paciente pediátrico em tratamento para leucemia linfoblástica aguda (LLA) e alertar quanto aos sinais que remetem a esses ...
Frederico Ribeiro Pires, Camila Abreu de Souza, Murilo Brito Luiz, Selma Harue Kawahara, Luiz Claudio Gonçalves de Castro   +4 more
doaj  

The optimal use of PEG-Asparaginase in relapsed ALL—lessons from the ALLR3 Clinical Trial [PDF]

Blood Cancer Journal, 2014
Though modern chemotherapy regimens cure over 80% of children with acute lymphoblastic leukaemia (ALL), the outcome of relapsed disease remains suboptimal. Current curative strategies for relapsed patients are based on high dose cytotoxic therapy often followed by an allogeneic stem cell transplant. Drug-related toxicities limits the intensification of
Masurekar, A., Fong, C., Hussein, A., Revesz, T., Hoogerbrugge, P.M., Hoogerbrugge, P.M., Love, S., Ciria, C., Parker, C., Krishnan, S., Saha, V.   +10 more
openaire   +5 more sources

National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?

BMC Cancer, 2020
Background L-asparaginase (L-ASP) is a key component of acute lymphoblastic leukemia (ALL) treatment, but its use in clinical practice raises challenges to clinicians due to a relatively high incidence of drug-related adverse events, mainly in adult ...
Federico Lussana, Paola Minetto, Felicetto Ferrara, Sabina Chiaretti, Giorgina Specchia, Renato Bassan   +5 more
doaj   +1 more source

Synthesis and characterization of L-asparaginase encapsulated Poly-l-lysine-graft-poly(ethylene) glycol polymer nanoparticles for potential therapeutic delivery applications [PDF]

, 2022
L-asparaginase (L-ASNase) is a therapeutic enzyme that is widely used for the treatment of hematopoietic diseases such as acute lymphoblastic leukemia and lymphomas since 1970.
NC DOCKS at Western Carolina University, Goff, Keri Joanna   +1 more
core